Catalyst

Slingshot members are tracking this event:

FDA set for Q3 2017 action date on AstraZeneca (AZN)'s Lynparza, or olaparib, for relapsed ovarian cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
AZN Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Relapsed Ovarian Cancer, Olaparib, Lynparza, Fda